Live search
TopFind is fetching the latest matches for your search.
We reviewed 545 live results for kanjinti trastuzumab 150 mg vial and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Source: Amgen
Description
Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies.
Best for
HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings
Rating
Source: Foris DAX MT
Description
Crypto.com is a global cryptocurrency exchange and financial services ecosystem founded in 2016. It operates under a robust regulatory framework with licenses in multiple jurisdictions, including a Major Payment Institution (MPI) license from the Monetary Authority of Singapore (MAS) and registration with the UK Financial Conduct Authority (FCA). The platform serves over 150 million users worldwide with a comprehensive suite of products, including spot and derivatives trading, the Crypto.com Visa Card (allowing users to spend crypto globally), "Earn" staking programs for passive income, and its native CRO token. Crypto.com is a legitimate financial technology company focused on building the infrastructure for the future of digital assets.
Best for
Users with limited data plans, Devices with less than 3GB of RAM and Users in areas with unstable network connectivity
Rating
Source: Amgen
Description
Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product.
Best for
Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology
Rating
| Compare | Crypto.com | Kanjinti (Trastuzumab) 150 mg/vial | Kanjinti (Trastuzumab) 440 mg/vial |
|---|---|---|---|
| Source | Foris DAX MT | Amgen | Amgen |
| Description | Crypto.com is a global cryptocurrency exchange and financial services ecosystem founded in 2016. It operates under a robust regulatory framework with licenses in multiple jurisdictions, including a Major Payment Institution (MPI) license from the Monetary Authority of Singapore (MAS) and registration with the UK Financial Conduct Authority (FCA). The platform serves over 150 million users worldwide with a comprehensive suite of products, including spot and derivatives trading, the Crypto.com Visa Card (allowing users to spend crypto globally), "Earn" staking programs for passive income, and its native CRO token. Crypto.com is a legitimate financial technology company focused on building the infrastructure for the future of digital assets. | Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies. | Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product. |
| Best for | Users with limited data plans, Devices with less than 3GB of RAM and Users in areas with unstable network connectivity | HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings | Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"Kanjinti (Trastuzumab) 150 mg/vial from Amgen."
I picked this because This biosimilar offer provides a clinically equivalent treatment to the reference biologic Herceptin for HER2-positive cancers, backed by HSA registration and Singapore National Drug Formulary listing.